Eisai sues FDA for more patent life
Tokyo-based drugmaker Eisai says the FDA owes it some extra patent time on weight-loss treatment Belviq and on epilepsy treatment Fycompa. Both drugs are classified by the Drug Enforcement Agency as controlled substances. While both were approved by the FDA, Eisai was unable to market either product until they were properly scheduled. Eisai claims it's entitled to one year of extra time on Belviq's patent and seven months on Fycompa's. The drugmaker made the claims in a lawsuit filed against the FDA in a bid to extend their market exclusivity.